NCT06504381 - DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2042

Conditions

High Grade GliomaMGMT-Unmethylated GlioblastomaMGMT-Methylated Glioblastoma

Interventions

GENETIC

DB107-RRV

Given intracranially (IC) during resection and intravenously (IV) immediately following

DRUG

DB107-FC

Given orally (PO)

RADIATION

Radiation Therapy (RT)

Undergo RT

DRUG

Temozolomide

Given PO

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo standard of care MRI

PROCEDURE

Surgical resection

Undergo non-investigational tumor resection

Trial Locations (4)

RECRUITING

University of Miami, Miami

RECRUITING

University of Southern California, Los Angeles

RECRUITING

University of California, San Diego, San Diego

RECRUITING

University of California, San Francisco